Michael Burgess actually said...
We cannot ignore that. We should not randomly categorize as bad actors those who have done what this committee has, frankly, encouraged them to do, investing in cutting-edge therapies like gene editing and regenerative medicine, because their list price is over an arbitrary amount.
Context
Advocates against labeling innovative drug developers as bad actors due to high prices.
05/20/2019